| 1 | 1. Tesofensine (NS 2330) | 1件: Tesofensine Tesofensine | - | - | - | 1件: 6 6 💬 |
| 2 | ACT-293987 (NS-304) | - | - | - | - | 1件: 86 86 💬 |
| 3 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
| 4 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone,
Bardoxolone methyl | 2件: Bardoxolone
Bardoxolone
,
Bardoxolone methyl
💬 | - | - | 1件: 86 86 💬 |
| 5 | Ch11-1F4 (NSC-711516) | - | - | - | - | 1件: 28 28 💬 |
| 6 | Corticosteroid or NSAID | - | - | - | - | 1件: 46 46 💬 |
| 7 | Ips-nsc cells | - | - | - | - | 1件: 6 6 💬 |
| 8 | Non-steroidal anti-inflammatory drug (NSAID) | - | - | - | - | 1件: 46 46 💬 |
| 9 | Non-steroidal anti-inflammatory drugs (NSAIDs) | - | - | - | - | 1件: 107 107 💬 |
| 10 | Norovirus -specific T-cell (NST) therapy | - | - | - | - | 1件: 65 65 💬 |
| 11 | NS | - | - | - | - | 1件: 2 2 💬 |
| 12 | NS 2330 | - | - | - | - | 1件: 6 6 💬 |
| 13 | NS-065/NCNP-01 | - | - | - | - | 1件: 113 113 💬 |
| 14 | NS-089/NCNP-02 | - | - | - | - | 1件: 113 113 💬 |
| 15 | NS-304 | - | - | - | - | 3件: 70 70, 86, 88 💬 |
| 16 | NS-304 Placebo | - | - | - | - | 2件: 70 70, 88 💬 |
| 17 | NS2 | - | - | - | - | 1件: 160 160 💬 |
| 18 | NS2330 | - | - | - | - | 1件: 6 6 💬 |
| 19 | NSAID | - | - | - | - | 1件: 271 271 💬 |
| 20 | NSAIDs | - | - | - | - | 4件: 46 46, 70, 107, 271 💬 |
| 21 | NSAIDs (permitted,not necessary) | - | - | - | - | 1件: 46 46 💬 |
| 22 | NSAIDs and sulfasalazine | 1件: Sulfasalazine Sulfasalazine | 1件: Sulfasalazine
Sulfasalazine
💬 | - | - | 1件: 271 271 💬 |
| 23 | NsNSAIDs | - | - | - | - | 2件: 107 107, 271 💬 |
| 24 | NSP001 | - | - | - | - | 1件: 96 96 💬 |
| 25 | Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac | 1件: Etodolac Etodolac | 1件: Etodolac
Etodolac
💬 | 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 💬 |
| 26 | Other Non-selective NSAIDs | - | - | - | - | 1件: 271 271 💬 |
| 27 | Patients' existing non-steroidal anti-inflammatory drug (NSAID) at approved doses | - | - | - | - | 1件: 46 46 💬 |
| 28 | Plantain NSP | - | - | - | - | 1件: 96 96 💬 |
| 29 | Recombinant human heparan Nsulfatase (rhHNS) | - | - | - | - | 1件: 19 19 💬 |
| 30 | Satralizumab (120 mg/PFS with NSD) | 1件: Satralizumab Satralizumab | 1件: Satralizumab
Satralizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
| 31 | Selexipag, ACT-293987 (NS-304) | 1件: Selexipag Selexipag | 1件: Selexipag
Selexipag
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |